cytarabine has been researched along with n(4)-oleylcytosine arabinoside in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barth, RF; Groscurth, P; Hengartner, H; Langhals, H; Schott, H; Schwendener, RA; Trüb, T | 1 |
| Koller-Lucae, SK; Schott, H; Schwendener, RA | 1 |
| Hänseler, E; Rentsch, KM; Schott, H; Schwendener, RA | 1 |
| Koller-Lucae, SK; Rentsch, KM; Schott, H; Schwendener, RA; Suter, MJ | 1 |
| Cattaneo-Pangrazzi, RM; Eriksson, S; Fichtner, I; Horber, DH; Ludwig, PS; Schott, H; Schwendener, RA; von Ballmoos, P | 1 |
| Cattaneo-Pangrazzi, RM; Schott, H; Schwendener, RA | 1 |
| Ballmer-Hofer, K; Langer-Machova, Z; Marty, C; Schott, H; Schwendener, RA; Sigrist, S | 1 |
| Hashida, M; Iwai, M; Kawakami, S; Terada, T; Yamashita, F | 1 |
| Knotts, TL; Mousa, SA | 1 |
| Simmons, D; Yu, D; Zhao, Z | 1 |
1 review(s) available for cytarabine and n(4)-oleylcytosine arabinoside
| Article | Year |
|---|---|
Anticoagulation in Venous Thromboembolism Prophylaxis in Medically Ill Patients: Potential Impact of NOACs.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Cytarabine; Factor Xa Inhibitors; Humans; Risk Factors; Venous Thromboembolism | 2019 |
9 other study(ies) available for cytarabine and n(4)-oleylcytosine arabinoside
| Article | Year |
|---|---|
Comparative studies of the preparation of immunoliposomes with the use of two bifunctional coupling agents and investigation of in vitro immunoliposome-target cell binding by cytofluorometry and electron microscopy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cross-Linking Reagents; Cytarabine; Drug Carriers; Flow Cytometry; Immunotoxins; Liposomes; Lymphoma; Maleimides; Mice; Microscopy, Electron; Microscopy, Electron, Scanning; Prodrugs; Rats; Succinimides; Sulfides; T-Lymphocytes; Tumor Cells, Cultured | 1990 |
Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-beta-D-arabinofuranosylcytosine, a new anticancer drug.
Topics: Animals; Antineoplastic Agents; Blood Proteins; Cytarabine; Drug Carriers; Erythrocytes; Female; Humans; Liposomes; Mice; Mice, Inbred ICR; Protein Binding | 1997 |
Pharmacokinetics of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in plasma and whole blood after intravenous and oral administration to mice.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Biological Availability; Chromatography, High Pressure Liquid; Cytarabine; Female; Injections, Intravenous; Intestinal Absorption; Metabolic Clearance Rate; Mice; Mice, Inbred ICR | 1997 |
Metabolism of the new liposomal anticancer drug N4-octadecyl-1-beta-D-arabinofuranosylcytosine in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chromatography, High Pressure Liquid; Chromatography, Liquid; Cytarabine; Feces; Female; Liposomes; Liver; Mass Spectrometry; Mice; Mice, Inbred ICR; Prodrugs | 1999 |
Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N4-alkyl-1-beta-D-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5'-->5')-N4-octadecyl-1-beta-D-arabinofuranosylcy
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cytarabine; Deoxycytidine Kinase; Dimerization; Disease Models, Animal; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Mice; Mice, Nude; Phosphates; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prodrugs; Transplantation, Heterologous | 2000 |
The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-145.
Topics: Androgens; Antimetabolites, Antineoplastic; Apoptosis; Biotransformation; Cell Cycle; Cell Division; Cytarabine; Dimerization; Dose-Response Relationship, Drug; Enzyme Inhibitors; Floxuridine; Fluorodeoxyuridylate; Humans; Hydrolysis; Male; Neoplasms, Hormone-Dependent; Phosphodiesterase I; Phosphoric Diester Hydrolases; Prodrugs; Prostatic Neoplasms; Thymidylate Synthase; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy.
Topics: Antibody Specificity; Antigens, CD; Antigens, Neoplasm; Cell Line; Cytarabine; Cytidine; Humans; Immunoglobulin Fragments; Liposomes; Membrane Proteins; Neoplasm Proteins; Neoplasms; Peptide Library; Recombinant Proteins | 2006 |
Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Culture Media, Conditioned; Cytarabine; Drug Delivery Systems; Galactose; Humans; Liposomes; Liver Neoplasms; Macrophages, Peritoneal; Matrix Metalloproteinase 2; Oligopeptides; Particle Size; Phosphatidylethanolamines | 2006 |
Cardiovascular risks and bleeding with non-vitamin K antagonist oral anticoagulant versus warfarin in patients with type 2 diabetes: a tapered matching cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cardiovascular Diseases; Comorbidity; Cytarabine; Diabetes Mellitus, Type 2; England; Female; Hemorrhage; Humans; Incidence; Male; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vitamin K; Warfarin | 2020 |